Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Healthcare stocks are generally more resilient in a challenging macro backdrop compared to stocks in other sectors. This is because the need for medicines and medical treatments i ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...

Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's top-line efficacy was in the same ballpark as Zepbound in the phase 3 readout.

GLP-1-directed drugs have already shown promise in clinical trials involving people with sleep apnoea – Lilly's Zepbound (tirzepatide) was approved for that indication in the US last year ...